Candel Therapeutics (NASDAQ:CADL – Get Free Report) and INmune Bio (NASDAQ:INMB – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.
Risk & Volatility
Candel Therapeutics has a beta of -1.2, meaning that its share price is 220% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.
Profitability
This table compares Candel Therapeutics and INmune Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Candel Therapeutics | N/A | -629.29% | -173.39% |
| INmune Bio | -26,333.59% | -117.48% | -78.96% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Candel Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| INmune Bio | 0 | 0 | 3 | 0 | 3.00 |
Candel Therapeutics presently has a consensus price target of $19.00, indicating a potential upside of 137.50%. INmune Bio has a consensus price target of $20.00, indicating a potential upside of 218.47%. Given INmune Bio’s higher possible upside, analysts clearly believe INmune Bio is more favorable than Candel Therapeutics.
Insider and Institutional Ownership
13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 41.6% of Candel Therapeutics shares are held by insiders. Comparatively, 35.2% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Candel Therapeutics and INmune Bio”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Candel Therapeutics | $120,000.00 | 2,165.07 | -$37.94 million | ($1.73) | -4.62 |
| INmune Bio | $42,000.00 | 3,315.24 | -$30.01 million | ($2.18) | -2.88 |
INmune Bio has lower revenue, but higher earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.
Summary
INmune Bio beats Candel Therapeutics on 8 of the 13 factors compared between the two stocks.
About Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
About INmune Bio
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
